n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Mesothelioma

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with Mesothelioma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baidoo, KE; Brechbiel, MW; Garmestani, K; Milenic, DE; Nayak, TK	1

Other Studies

1 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Mesothelioma

Article	Year
HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PloS one, 2011, Mar-25, Volume: 6, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody Specificity; Cetuximab; ErbB Receptors; Flow Cytometry; Humans; Isothiocyanates; Mesothelioma; Mice; Molecular Targeted Therapy; Panitumumab; Pentetic Acid; Positron-Emission Tomography; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2011

Article

Year

HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.

PloS one, 2011, Mar-25, Volume: 6, Issue:3

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody Specificity; Cetuximab; ErbB Receptors; Flow Cytometry; Humans; Isothiocyanates; Mesothelioma; Mice; Molecular Targeted Therapy; Panitumumab; Pentetic Acid; Positron-Emission Tomography; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2011